- call +1-201-465-4211
- email sales@mrinsights.biz
Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
Scope of the Report:
This report focuses on the Pet Cancer Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth.
The worldwide market for Pet Cancer Therapeutics is expected to grow at a CAGR of roughly 7.9% over the next five years, will reach 290 million US$ in 2023, from 180 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Aratana Therapeutics, Inc
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc
VetDC, Inc
Karyopharm Therapeutics, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy
Market Segment by Applications, can be divided into
Lymphoma
Mast Cell Cancer
Melanoma
Mammary
Squamous Cell Cancer
Others
There are 15 Chapters to deeply display the global Pet Cancer Therapeutics market.
Chapter 1, to describe Pet Cancer Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Pet Cancer Therapeutics, with sales, revenue, and price of Pet Cancer Therapeutics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Pet Cancer Therapeutics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Pet Cancer Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Pet Cancer Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Pet Cancer Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Chemotherapy
1.2.2 Targeted Therapy
1.2.3 Combination Therapy
1.2.4 Immunotherapy
1.3 Market Analysis by Applications
1.3.1 Lymphoma
1.3.2 Mast Cell Cancer
1.3.3 Melanoma
1.3.4 Mammary
1.3.5 Squamous Cell Cancer
1.3.6 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Aratana Therapeutics, Inc
2.1.1 Business Overview
2.1.2 Pet Cancer Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Aratana Therapeutics, Inc Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 AB Science
2.2.1 Business Overview
2.2.2 Pet Cancer Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AB Science Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Boehringer Ingelheim International GmbH
2.3.1 Business Overview
2.3.2 Pet Cancer Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Zenoaq
2.4.1 Business Overview
2.4.2 Pet Cancer Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Zenoaq Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Morphogenesis, Inc
2.5.1 Business Overview
2.5.2 Pet Cancer Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Morphogenesis, Inc Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 VetDC, Inc
2.6.1 Business Overview
2.6.2 Pet Cancer Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 VetDC, Inc Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Karyopharm Therapeutics, Inc
2.7.1 Business Overview
2.7.2 Pet Cancer Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Rhizen Pharmaceutical SA
2.8.1 Business Overview
2.8.2 Pet Cancer Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Regeneus Ltd.
2.9.1 Business Overview
2.9.2 Pet Cancer Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Regeneus Ltd. Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Oasmia Pharmaceuticals AB
2.10.1 Business Overview
2.10.2 Pet Cancer Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Zoetis
2.11.1 Business Overview
2.11.2 Pet Cancer Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Zoetis Pet Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Pet Cancer Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Pet Cancer Therapeutics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Pet Cancer Therapeutics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Pet Cancer Therapeutics Manufacturer Market Share in 2017
3.3.2 Top 6 Pet Cancer Therapeutics Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Pet Cancer Therapeutics Market Analysis by Regions
4.1 Global Pet Cancer Therapeutics Sales, Revenue and Market Share by Regions
4.1.1 Global Pet Cancer Therapeutics Sales and Market Share by Regions (2013-2018)
4.1.2 Global Pet Cancer Therapeutics Revenue and Market Share by Regions (2013-2018)
4.2 North America Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
4.3 Europe Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
4.5 South America Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
5 North America Pet Cancer Therapeutics by Countries
5.1 North America Pet Cancer Therapeutics Sales, Revenue and Market Share by Countries
5.1.1 North America Pet Cancer Therapeutics Sales and Market Share by Countries (2013-2018)
5.1.2 North America Pet Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)
5.2 United States Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
5.3 Canada Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
5.4 Mexico Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
6 Europe Pet Cancer Therapeutics by Countries
6.1 Europe Pet Cancer Therapeutics Sales, Revenue and Market Share by Countries
6.1.1 Europe Pet Cancer Therapeutics Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Pet Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)
6.2 Germany Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
6.3 UK Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
6.4 France Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
6.5 Russia Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
6.6 Italy Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
7 Asia-Pacific Pet Cancer Therapeutics by Countries
7.1 Asia-Pacific Pet Cancer Therapeutics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Pet Cancer Therapeutics Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Pet Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)
7.2 China Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
7.3 Japan Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
7.4 Korea Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
7.5 India Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
8 South America Pet Cancer Therapeutics by Countries
8.1 South America Pet Cancer Therapeutics Sales, Revenue and Market Share by Countries
8.1.1 South America Pet Cancer Therapeutics Sales and Market Share by Countries (2013-2018)
8.1.2 South America Pet Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
8.3 Argentina Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
8.4 Colombia Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
9 Middle East and Africa Pet Cancer Therapeutics by Countries
9.1 Middle East and Africa Pet Cancer Therapeutics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Pet Cancer Therapeutics Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Pet Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
9.3 UAE Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
9.4 Egypt Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
9.5 Nigeria Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
9.6 South Africa Pet Cancer Therapeutics Sales and Growth Rate (2013-2018)
10 Global Pet Cancer Therapeutics Market Segment by Type
10.1 Global Pet Cancer Therapeutics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Pet Cancer Therapeutics Sales and Market Share by Type (2013-2018)
10.1.2 Global Pet Cancer Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Chemotherapy Sales Growth and Price
10.2.1 Global Chemotherapy Sales Growth (2013-2018)
10.2.2 Global Chemotherapy Price (2013-2018)
10.3 Targeted Therapy Sales Growth and Price
10.3.1 Global Targeted Therapy Sales Growth (2013-2018)
10.3.2 Global Targeted Therapy Price (2013-2018)
10.4 Combination Therapy Sales Growth and Price
10.4.1 Global Combination Therapy Sales Growth (2013-2018)
10.4.2 Global Combination Therapy Price (2013-2018)
10.5 Immunotherapy Sales Growth and Price
10.5.1 Global Immunotherapy Sales Growth (2013-2018)
10.5.2 Global Immunotherapy Price (2013-2018)
11 Global Pet Cancer Therapeutics Market Segment by Application
11.1 Global Pet Cancer Therapeutics Sales Market Share by Application (2013-2018)
11.2 Lymphoma Sales Growth (2013-2018)
11.3 Mast Cell Cancer Sales Growth (2013-2018)
11.4 Melanoma Sales Growth (2013-2018)
11.5 Mammary Sales Growth (2013-2018)
11.6 Squamous Cell Cancer Sales Growth (2013-2018)
11.7 Others Sales Growth (2013-2018)
12 Pet Cancer Therapeutics Market Forecast (2018-2023)
12.1 Global Pet Cancer Therapeutics Sales, Revenue and Growth Rate (2018-2023)
12.2 Pet Cancer Therapeutics Market Forecast by Regions (2018-2023)
12.2.1 North America Pet Cancer Therapeutics Market Forecast (2018-2023)
12.2.2 Europe Pet Cancer Therapeutics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Pet Cancer Therapeutics Market Forecast (2018-2023)
12.2.4 South America Pet Cancer Therapeutics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Pet Cancer Therapeutics Market Forecast (2018-2023)
12.3 Pet Cancer Therapeutics Market Forecast by Type (2018-2023)
12.3.1 Global Pet Cancer Therapeutics Sales Forecast by Type (2018-2023)
12.3.2 Global Pet Cancer Therapeutics Market Share Forecast by Type (2018-2023)
12.4 Pet Cancer Therapeutics Market Forecast by Application (2018-2023)
12.4.1 Global Pet Cancer Therapeutics Sales Forecast by Application (2018-2023)
12.4.2 Global Pet Cancer Therapeutics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Pet Cancer Therapeutics Picture
Table Product Specifications of Pet Cancer Therapeutics
Figure Global Sales Market Share of Pet Cancer Therapeutics by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
